Heredity

NCCN Updates Treatment Recommendations for Breast, Colorectal, Lung, and other Cancer Types Based on Emerging Evidence

Retrieved on: 
星期一, 三月 4, 2024
Classification, Neoplasm, MD, System, Heredity, Bladder cancer, Lung, Principle, Conference, Breast, Lung cancer, Kidney cancer, NCCN, Pathology, Patient, Virtual, National Comprehensive Cancer Network, Medicine, Poster, Research, Medical imaging

PLYMOUTH MEETING, Pa., March 4, 2024 /PRNewswire/ -- The National Comprehensive Cancer Network® (NCCN®) is announcing several new updates to the cancer treatment practices listed in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). The evidence-based expert consensus recommendations are the most frequently updated guidelines for any area of medicine and are used by cancer care providers worldwide to stay up to date on innovations. Recently, the alliance of leading cancer centers published updated versions for several high-incidence cancer types, including breast, colorectal, lung, and pancreatic.

Key Points: 
  • Latest recommendations and underlying evidence will be explained at NCCN 2024 Annual Conference April 5-7.
  • PLYMOUTH MEETING, Pa., March 4, 2024 /PRNewswire/ -- The National Comprehensive Cancer Network® (NCCN®) is announcing several new updates to the cancer treatment practices listed in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®).
  • Recently, the alliance of leading cancer centers published updated versions for several high-incidence cancer types, including breast, colorectal, lung, and pancreatic.
  • Some recent updates to the NCCN Guidelines recommendations include:
    Updates to treatment of HR-positive, early-stage breast cancer, including a new page outlining the general principles for adjuvant endocrine therapy.

Urology Care Foundation Spreads Awareness for National Cancer Prevention Month

Retrieved on: 
星期三, 一月 31, 2024
Education, Ache, Penile cancer, Urethral cancer, Urination, Kidney cancer, Bleeding, Fluid mechanics, Testicular cancer, Heredity, Urethra, Radiation, Back pain, Infection, Bladder cancer, Abdomen, Foreskin, Weight loss, FACS, Fever, Groin, Risk factor, Diet, AUA, Blog, Cancer, HPV, Combustion, Woman, Urethral caruncle, Growth, Papillomaviridae, Prostate cancer, Low back pain, Penis, Urethral diverticulum, Rib, Death, Skin, Blood, Disease, AIDS, Risk, Ejaculation, Smoking, Workplace, UTI, American Urological Association, Male, Scrotum, Pain, Tenderness, MBA, Somatic symptom disorder, Urine, Smoker, GCNIS, Ulcer, Birth control

BALTIMORE, Jan. 31, 2024 (GLOBE NEWSWIRE) -- February is National Cancer Prevention Month, and the Urology Care Foundation, the official foundation of the American Urological Association (AUA), wants to spread awareness and information on the six main urologic cancers.

Key Points: 
  • BALTIMORE, Jan. 31, 2024 (GLOBE NEWSWIRE) -- February is National Cancer Prevention Month, and the Urology Care Foundation, the official foundation of the American Urological Association (AUA), wants to spread awareness and information on the six main urologic cancers.
  • However, there are other urologic cancers that involve the bladder, kidneys and testicles,” said Urology Care Foundation Board of Directors member Brian McNeil, MD, MBA, FACS.
  • The Urology Care Foundation believes the first part of prevention is education.
  • Below are the six main urologic cancers and important resources for each:
    Bladder Cancer is the second most common type of urologic cancer.

Gitanyow Nation Launches Defensive Stance Against Potential Transfer of Forestry License 16882

Retrieved on: 
星期四, 十二月 14, 2023
Marketing, Terrace Mill, Government, Bankruptcy, Kitwanga, Gitanyow, GHC, Heredity, Property management

This forestry license, deeply intertwined with Gitanyow’s traditional lands, presents an unmistakable and high potential for substantial adverse impacts on Gitanyow’s rights.

Key Points: 
  • This forestry license, deeply intertwined with Gitanyow’s traditional lands, presents an unmistakable and high potential for substantial adverse impacts on Gitanyow’s rights.
  • Despite a Cooperative Harvest Agreement previously in place with Gitanyow, SS's recent bankruptcy has put its assets, including FLA16882, in receivership.
  • The Simigigyet’m Gitanyow (Gitanyow Hereditary Chiefs) are an innovative, traditional Indigenous government mandated to protect Gitanyow Nation’s lands, resources, and laws.
  • Gitanyow Nation is part of the larger Gitksan Nation, encompassing 6,200 square kilometres in the Nass and Skeena Watersheds (Kitwanga and Kispiox Rivers).

WAINUA™ (eplontersen) Granted First-Ever Regulatory Approval in the US for the Treatment of Adults With Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis

Retrieved on: 
星期五, 十二月 22, 2023
Research, FDA, Neurology, Genetics, Clinical Trials, Biotechnology, Health, Pharmaceutical, Science, Quality of life, Tissue, Heart, Heredity, Serum, Polyneuropathy, Death, Inotersen, Ageing, TTR, JAMA, Vitamin A, Diagnosis, Metabolism, Amyloidosis, Pancreas, Disease, Safety, Journal, Heart failure, Disability studies, Sympathetic nervous system, Vitamin A deficiency, Food, Biopharmaceutical, AstraZeneca, Caregiver, ATTR, Patient, Medicine, LICA, Ionis, American Medical Association, Growth, Central nervous system, Pharmaceutical industry

It is also a pivotal moment for Ionis as WAINUA will be the first in a steady cadence of potential commercial launches for the company.

Key Points: 
  • It is also a pivotal moment for Ionis as WAINUA will be the first in a steady cadence of potential commercial launches for the company.
  • Reduced Serum Vitamin A Levels and Recommended Supplementation WAINUA leads to a decrease in serum vitamin A levels.
  • Refer patient to an ophthalmologist if ocular symptoms suggestive of vitamin A deficiency occur.
  • Please see link to US Full Prescribing Information for WAINUA.

The 5th World Media Summit (Yunnan, China) and the 2nd Yunnan International Communication Forum kicks off

Retrieved on: 
星期二, 十二月 12, 2023
Destinations, Media, Travel, Vacation, Communications, Arts, Museums, Tourist Attractions, Entertainment, Belt, Multimedia, Ecosystem, Han Chinese, Heredity, Plant, City, Belt and Road Initiative, Kingdom of Plants 3D, System, Biodiversity, Tea, Animal

More than 300 representatives of around 80 institutions, including media outlets, international organizations and think tanks, from nearly 30 countries and regions, gathered in Yunnan for the fifth World Media Summit and the second Yunnan International Communication Forum, which kicked off on December 5 in Kunming, the capital city of province Yunnan in southwest China.

Key Points: 
  • More than 300 representatives of around 80 institutions, including media outlets, international organizations and think tanks, from nearly 30 countries and regions, gathered in Yunnan for the fifth World Media Summit and the second Yunnan International Communication Forum, which kicked off on December 5 in Kunming, the capital city of province Yunnan in southwest China.
  • View the full release here: https://www.businesswire.com/news/home/20231211302806/en/
    The 5th World Media Summit (Yunnan Branch) and the 2nd Yunnan International Communication Forum kicks off in Kunming on Dec. 5 (Photo: Business Wire)
    While the Kunming Initiative has been adopted at the opening of the summit on 5th Dec., a theme activity named “There is a lifestyle called Yunnan” has been launched, and the international communication hot words list has been released by the Chinese media Xinhuanet.
  • Yunnan is the most ethnically diverse province in China, with 25 hereditary ethnic minorities in addition to the Han Chinese.
  • Now, Yunnan is creating an ecologically green, colorful, harmonious, and happy, open and inclusive “There is a lifestyle called Yunnan."

Asia-Pacific Nucleic Acid Therapeutics CDMO Market Report 2023-2033: Continued R&D for Manufacturing Innovative Nucleic Acid Therapeutics Forcing Pharmaceutical Companies to Expand their Businesses - ResearchAndMarkets.com

Retrieved on: 
星期三, 十二月 6, 2023
Health, Other Health, Investment, Growth, Therapy, Patient, Incidence, CDMO, Heredity, Vaccine

The "Asia-Pacific Nucleic Acid Therapeutics CDMO Market - Analysis and Forecast, 2023-2033" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Asia-Pacific Nucleic Acid Therapeutics CDMO Market - Analysis and Forecast, 2023-2033" report has been added to ResearchAndMarkets.com's offering.
  • The APAC Nucleic Acid Therapeutics CDMO Market is expected to grow at a CAGR of 13.92% from $0.97 billion in 2022 to $4.04 billion by 2033 in the forecasted period of 2023-2033.
  • The Asia-Pacific nucleic acid therapeutics CDMO market has witnessed several investments for the expansion of CDMO manufacturing units by the market players.
  • With the rising incidence of genetic and chronic illnesses, growing regulatory approvals, growing CDMO manufacturing infrastructure, and encouraging government initiatives, the APAC nucleic acid therapeutics CDMO market is expected to grow significantly in the next years.

AvevoRx Secures Limited Distribution Agreement for Alpha-1 Proteinase Inhibitor Zemaira®

Retrieved on: 
星期二, 十二月 5, 2023
CSL, Therapy, Patient, Heredity, Pharmaceutical industry

GREENSBORO, N.C., Dec. 5, 2023 /PRNewswire-PRWeb/ -- AvevoRx, a national, independent provider of specialty infusion pharmacy services, has secured a limited distribution deal for the Alpha-1 proteinase inhibitor (Human) Zemaira®. The treatment is the latest in AvevoRx's already robust therapy offerings for patients with an Alpha-1 deficiency, a hereditary and progressive condition that affects the lungs.

Key Points: 
  • Deal comes just months after AvevoRx announces an initial foray into the Alpha-1 market, adding to its already robust therapy offering for patients with the Alpha-1 deficiency
    GREENSBORO, N.C., Dec. 5, 2023 /PRNewswire-PRWeb/ -- AvevoRx, a national, independent provider of specialty infusion pharmacy services, has secured a limited distribution deal for the Alpha-1 proteinase inhibitor (Human) Zemaira®.
  • The treatment is the latest in AvevoRx's already robust therapy offerings for patients with an Alpha-1 deficiency, a hereditary and progressive condition that affects the lungs.
  • Ric Logsdon, program manager for AvevoRx, says the timing is right for both the company and the Alpha-1 community.
  • "We are proud to now offer our growing number of patients the option of Zemaira as a therapy to help their Alpha-1 deficiency."

23andMe Launches Total Health™, its Comprehensive, Prevention-Based Health Membership

Retrieved on: 
星期二, 十一月 7, 2023
Knowledge, FDA, Medical genetics, American College, 23andMe, DPYD, Genetic testing, ACMG, Polygene, Biomarker, Health, Ovarian cancer, Therapy, Life, BRCA1, Reading, Genetics, Citalopram, Liver, Kidney, Research, Prostate cancer, Clinical Pharmacogenetics Implementation Consortium, Pharmacogenomics, Metabolism, Genomic Health, BRCA2, Genome, Heredity, Disease, LDL, CYP2C19, Risk, Asthma, Risk assessment, Cancer, Breast cancer, Saliva, Pancreatic cancer, PGS, Fetus, Gene, SLCO1B1, Anxiety, Breast, American College of Medical Genetics and Genomics, Lijun International Pharmaceutical (Holding) Co. Ltd., Cholesterol, SAN, DNA, Pharmaceutical industry, Medical imaging, Vaccine, Medical device, Dietary supplement

SOUTH SAN FRANCISCO, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading genetic health and biopharmaceutical company, today launched 23andMe+ Total Health, its new, comprehensive prevention-based health membership that provides clinical grade exome sequencing, biannual blood testing, and unprecedented access to genetics-based clinical care.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading genetic health and biopharmaceutical company, today launched 23andMe+ Total Health, its new, comprehensive prevention-based health membership that provides clinical grade exome sequencing, biannual blood testing, and unprecedented access to genetics-based clinical care.
  • Members of Total Health will also receive all the reports and features offered in the Company’s existing 23andMe+ Premium Membership .
  • As part of Total Health, members will gain access to all the premium reports and features delivered through 23andMe+ Premium.
  • The 23andMe+ Total Health membership will cost $99 per month, billed in a one-time annual payment of $1,188.

MHTC and Cancer Care Experts Join Forces, Fuelled by #Thrive365, to Shine a Light on Breast Cancer Awareness Month

Retrieved on: 
星期六, 十月 14, 2023
Yee, Knowledge, Breast cancer, Heredity, Disease, Breast, Environment, Statistics, Breast-conserving surgery, History, Birth control

The event aimed to create more awareness on the importance of early detection and provide valuable insights into breast cancer prevention and screening methods.

Key Points: 
  • The event aimed to create more awareness on the importance of early detection and provide valuable insights into breast cancer prevention and screening methods.
  • The panel discussion is aligned with this year's breast cancer awareness month theme, Thrive365.
  • Breast cancer affects both genders, and it is crucial to raise awareness about the disease among men as well.
  • Through initiatives like discussions, MHTC aims to empower individuals with knowledge and encourage proactive steps towards breast cancer prevention and early detection.

PreCheck Health Genetic Testing: A Vital Tool in the Battle Against Hereditary Cancers

Retrieved on: 
星期四, 十月 12, 2023
Health, Knowledge, Cancer, Physician, Hope, Breast cancer, Breast, BRCA2, Risk, Heredity, Genetic, Genetic testing, Genetics, Mutation, BRCA1, Role, Ovarian cancer, Weakness, Fatigue, USPSTF, BRCA, Dizziness, Patient, Colon, Colorectal cancer, Uncertainty, Ovary, Vaccine, Birth control, Mobile phone, Dietary supplement, Nursing

PreCheck Health, we'll delve into the significance of genetic testing in identifying hereditary cancer risks and its role in promoting early screening.

Key Points: 
  • PreCheck Health, we'll delve into the significance of genetic testing in identifying hereditary cancer risks and its role in promoting early screening.
  • Learn why genetic testing is crucial for patients with a strong family history of breast, colon, and ovarian cancers.
  • But what exactly makes these cancers so hereditary, and how can genetic testing help in early detection and prevention?
  • The Role of Genetic Factors: In hereditary cancers, specific gene mutations are passed down from one generation to the next.